Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides

被引:131
作者
Lambert, G
Fattal, E
Pinto-Alphandary, H
Gulik, A
Couvreur, P [1 ]
机构
[1] Univ Paris 11, Fac Pharm, UMR CNRS 8612, Lab Physicochim Pharmacotechnie & Biopharm, F-92290 Chatenay Malabry, France
[2] CNRS, Ctr Genet Mol, Gif Sur Yvette, France
关键词
nanoparticles; nanocapsules; nanospheres; polyisobutylcyanoacrylate; oligonucleotides; antisense;
D O I
10.1023/A:1007582332491
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. The goal of the present paper was to encapsulate oligonucleotides in a new particulate carrier in order to protect them from enzymatic degradation. Methods. Nanocapsules with an aqueous core containing oligonucleotides were prepared by interfacial polymerization of isobutylcyanoacrylate in a W/O emulsion. Ultracentrifugation and re-suspension in water yielded a dispersion of these containing an aqueous core nanocapsules. Zeta potential measurements and quenching of fluorescence of fluorescein-bounded oligonucleotides were used to study the localization of the oligonucleotides. Oligonucleotide degradation studies were carried out in fetal calf serum. Results. Polydisperse nanocapsules of size ranging from 20 to 400 nm were obtained. Oligonucleotide loading did not significantly influence the zeta potential, suggesting they were located within the core of the nanocapsules. Fluorescence quenching assays confirmed this localization. When encapsulated in the nanocapsules and incubated in the presence of serum, the oligonucleotides were efficiently protected from degradation by nucleases, whereas oligonucleotides adsorbed onto nanospheres were protected less efficiently. Conclusions, This paper describes, for the first time, a nanotechnology able to encapsulate oligonucleotides rather than adsorbing them at the surface of a solid support. Such a formulation has great potential for oligonucleotide delivery.
引用
收藏
页码:707 / 714
页数:8
相关论文
共 31 条
[1]   Spongelike alginate nanoparticles as a new potential system for the delivery of antisense oligonucleotides [J].
Aynié, I ;
Vauthier, C ;
Chacun, H ;
Fattal, E ;
Couvreur, P .
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 1999, 9 (03) :301-312
[2]   Development of a quantitative polyacrylamide gel electrophoresis analysis using a multichannel radioactivity counter for the evaluation of oligonucleotide-bound drug carrier [J].
Aynie, I ;
Vauthier, C ;
Foulquier, M ;
Malvy, C ;
Fattal, E ;
Couvreur, P .
ANALYTICAL BIOCHEMISTRY, 1996, 240 (02) :202-209
[3]   REGULATORY CONSIDERATIONS FOR OLIGONUCLEOTIDE DRUGS - UPDATED RECOMMENDATIONS FOR PHARMACOLOGY AND TOXICOLOGY STUDIES [J].
BLACK, LE ;
FARRELLY, JG ;
CAVAGNARO, JA ;
AHN, CH ;
DEGEORGE, JJ ;
TAYLOR, AS ;
DEFELICE, AF ;
JORDAN, A .
ANTISENSE RESEARCH AND DEVELOPMENT, 1994, 4 (04) :299-301
[4]   Cationic liposome-encapsulated antisense oligonucleotide mediates efficient killing of intracellular Leishmania [J].
Chakraborty, R ;
Dasgupta, D ;
Adhya, S ;
Basu, MK .
BIOCHEMICAL JOURNAL, 1999, 340 :393-396
[5]   ADSORPTION OF OLIGONUCLEOTIDES ONTO POLYISOHEXYLCYANOACRYLATE NANOPARTICLES PROTECTS THEM AGAINST NUCLEASES AND INCREASES THEIR CELLULAR UPTAKE [J].
CHAVANY, C ;
SAISONBEHMOARAS, T ;
LEDOAN, T ;
PUISIEUX, F ;
COUVREUR, P ;
HELENE, C .
PHARMACEUTICAL RESEARCH, 1994, 11 (09) :1370-1378
[6]   POLYALKYLCYANOACRYLATE NANOPARTICLES AS POLYMERIC CARRIERS FOR ANTISENSE OLIGONUCLEOTIDES [J].
CHAVANY, C ;
LEDOAN, T ;
COUVREUR, P ;
PUISIEUX, F ;
HELENE, C .
PHARMACEUTICAL RESEARCH, 1992, 9 (04) :441-449
[7]   ADSORPTION OF ANTI-NEOPLASTIC DRUGS TO POLYALKYLCYANOACRYLATE NANOPARTICLES AND THEIR RELEASE IN CALF SERUM [J].
COUVREUR, P ;
KANTE, B ;
ROLAND, M ;
SPEISER, P .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1979, 68 (12) :1521-1524
[8]  
Dean N, 1996, CANCER RES, V56, P3499
[9]   BACKBONE MODIFICATIONS IN OLIGONUCLEOTIDES AND PEPTIDE NUCLEIC-ACID SYSTEMS [J].
DEMESMAEKER, A ;
ALTMANN, KH ;
WALDNER, A ;
WENDEBORN, S .
CURRENT OPINION IN STRUCTURAL BIOLOGY, 1995, 5 (03) :343-355
[10]  
FALLOUH NA, 1986, INT J PHARM, V28, P125